http://www.fpnotebook.com/
Leukotriene Receptor AntagonistAka: Leukotriene Synthesis Inhibitor, Accolate, Zafirlukast, Montelukast, Singulair, Zileuton, Zyflo
- Preparations
- Zafirlukast (Accolate)
- Montelukast (Singulair)
- Zileuton (Zyflo)
- Mechanism
- Attenuates bronchoconstriction and inflammation
- Leukotriene receptor antagonists
- Zafirlukast (Accolate)
- Montelukast (Singulair)
- Leukotriene Synthesis Inhibitor
- Zileuton (Zyflo)
- Indication: Adjunctive in Asthma and Allergic Rhinitis
- Dosing: Zafirlukast (Accolate)
- Leukotriene Receptor Antagonist
- Avoid at mealtime
- Take 1 hour before or 2 hours after meals
- Dose
- Age >11 years old: 20 mg PO bid
- Child 7-11 years old: 10 mg PO bid
- Dosing: Montelukast (Singulair)
- Leukotriene Receptor Antagonist
- Dose
- Adults: 10 mg PO qhs
- Child age 6 to 14 years: 5 mg PO qhs
- Child age 2-5 years: 4 mg PO qhs
- Dosing: Zileuton (Zyflo)
- Leukotriene Synthesis Inhibitor
- Indicated in age only 12 and over
- Dose: 600 mg orally four times daily
- Hepatotoxicity in 5% (Monitor liver enzymes q3 months)
- Drug interactions: Warfarin, theophylline, Propranolol
- Expensive ($273 per month)
- Efficacy
- Modestly effective for maintenance management
- Inhaled Steroids are preferred over leukotriene agents
- Used as adjunctive therapy in Asthma
- Benefit may be limited to patients with the 5-LO and LTC4 polymorphisms
- Adverse Effects
- Multiple P450 drug interactions
- Potentiates Warfarin
- Potentiates Theophylline
- Potentiates Propranolol
- Some association with Churg-Strauss Syndrome
- Systemic Eosinophilic Vasculitis
- Vasculitic rash
- Pulmonary and cardiac conditions
- Hepatotoxicity with Zileuton (Zyflo)
- Multiple P450 drug interactions
- Cost
- Among most expensive agents in Asthma
- Accolate and Singulair: $90-100 per month
- Zyflo: $270 per month
- References
zileuton (C0081408) | |
|---|---|
| Definition (PDQ) | A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=285649&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C26667" NCI Thesaurus) |
| Definition (NCI) | A synthetic derivative of hydroxyurea with antiasthmatic properties. The leukotriene inhibitor zileuton blocks 5-lipoxygenase, which catalyzes the formation of leukotrienes from arachidonic acid; causes bronchodilation; decreases bronchial mucous secretion and edema; and may prevent or decrease the symptoms of asthma. (NCI04) |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C063449 |
| English | zileuton, ZILEUTON PREPARATION, ZLT |
| Spanish | zileutona |
| Parent Concepts | Lipooxygenase Inhibitor (C1517903), hydroxyurea (C0020402), [RE108] ANTIASTHMA, ANTILEUKOTRIENES (C0973620), Respiratory smooth muscle relaxant (C0304440), 5-lipoxygenase inhibitor (C1289971), Leukotriene Antagonists (C0595726) |
| Sources | MSH, MTHSPL, NCI, NDFRT, PDQ, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
montelukast (C0298130) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C093875 |
| English | montelukast, Montelukast agent, MONTELUKAST PREPARATION, Montelukast product |
| Spanish | agente con montelukast, montelukast |
| Parent Concepts | Bronchodilator Agents (C0006280), Acetates (C0000979), Quinolines (C0034424), [RE109] ANTIASTHMA, OTHER (C0973621), Leukotriene Antagonists (C0595726), Duplicate concept (C1274013) |
| Sources | MSH, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
zafirlukast (C0378466) | |
|---|---|
| Definition (NCI) | A toyl compound with anti-asthmatic property. Zafirlukast selectively and competitively binds and blocks the cysteinyl leukotriene 1 receptor , thereby preventing potent proinflammatory mediators leukotriene C4, D4 and E4 from binding. This prevents leukotriene-mediated actions, including enhanced migration of eosinophils and neutrophils, increased adhesion of leukocytes, increased monocyte and neutrophil aggregation, increased airway edema, inflammation, capillary permeability and bronchoconstriction. |
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C062735 |
| English | zafirlukast, ZAFIRLUKAST PREPARATION |
| Spanish | zafirlukast |
| Parent Concepts | Anti-Asthmatic Agents (C0282556), Tosyl Compounds (C0040493), [RE108] ANTIASTHMA, ANTILEUKOTRIENES (C0973620), Leukotriene Antagonists (C0595726), Duplicate concept (C1274013) |
| Sources | MSH, MTHSPL, NCI, NDFRT, RXNORM, SCTSPA, SNOMEDCT, USPMG, VANDF Derived from the NIH UMLS (Unified Medical Language System) |
Accolate (C0526502) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C062735 |
| English | Accolate, AstraZeneca brand of zafirlukast, Zeneca brand of zafirkulast |
| Sources | MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
Singulair (C0595724) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C093875 |
| English | Cahill May Roberts brand of montelukast sodium, Merck brand of montelukast sodium, Merck Frosst brand of montelukast sodium, Merck Sharp & Dohme brand of montelukast sodium, Singulair |
| Sources | MSH, NCI, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
Zyflo (C0724508) | |
|---|---|
| Concepts | Organic Chemical (T109) , Pharmacologic Substance (T121) |
| MSH | C063449 |
| English | Abbott brand of zileuton, Zyflo |
| Sources | MSH, NCI, PDQ, RXNORM Derived from the NIH UMLS (Unified Medical Language System) |
